Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
Dallas-based Meros Investment Management purchased 159,945 shares of Azenta valued at $4.6 million in the third quarter. The position represents 2% of Meros’s 13F reportable assets under management.
A collaborative effort by the Formosa-Jordan lab from the Max Planck Institute for Plant Breeding Research in Cologne, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback